GeneDx Holdings (WGS) Revenue (2020 - 2026)

GeneDx Holdings has disclosed Revenue across 7 years of filings, most recently posting $102.3 million for Q1 2026.

• In Q1 2026, Revenue rose 17.38% year-over-year to $102.3 million; the TTM figure through Mar 2026 stood at $442.7 million (up 34.09% YoY), while the FY2025 annual figure was $427.5 million, up 39.97% from the prior year.
• Revenue retreated to $102.3 million in Q1 2026, from $121.0 million in the prior quarter.
• Over the last five years, Revenue for WGS reached as high as $121.0 million in Q4 2025 and fell as low as $36.2 million in Q2 2022.
• The 5-year median for Revenue is $70.5 million (2024), against an average of $74.9 million.
• Annual changes were most pronounced in 2022 — Revenue soared 92.77% — and 2023, when it tumbled 35.96%.
• A 5-year view of Revenue shows it stood at $61.4 million in 2022, then declined by 6.41% to $57.4 million in 2023, then surged by 66.57% to $95.6 million in 2024, then advanced by 26.5% to $121.0 million in 2025, then decreased by 15.48% to $102.3 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $102.3 million, $121.0 million, and $116.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.